Journal for ImmunoTherapy of Cancer

SJR Rank #415H-index: 155SJR: 4.114Best quartile: Q1Open AccessAPC: US$2,490Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

BMJ Publishing Group

Country

United Kingdom

Type

journal

SJR by Edition

2022202502468

Subject Categories

  • Cancer ResearchQ1
  • ImmunologyQ1
  • Immunology and AllergyQ1
  • Molecular MedicineQ1
  • OncologyQ1
  • PharmacologyQ1

Areas: Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · Medicine · Pharmacology, Toxicology and Pharmaceutics

Most published research topics

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy researchImmune Cell Function and InteractionImmune cells in cancerMonoclonal and Polyclonal Antibodies ResearchVirus-based gene therapy researchFerroptosis and cancer prognosisCancer Research and TreatmentsT-cell and B-cell Immunology

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs040080012001600

Documents per Year

202220250200400600800

Detailed Information

ISSN

2051-1426

SJR Best Quartile

Q1

Region

Western Europe

Citations per Document (2 years)

9.58

References per Document

44.04

Coverage

2013-2026

Scope

The Journal for ImmunoTherapy of Cancer (JITC) is the open access, peer reviewed, online journal of the Society for Immunotherapy of Cancer (SITC). The journal publishes articles on all aspects of tumor immunology and cancer immunotherapy and, in doing so, aims to enrich communication and advance scientific understanding among the many stakeholders in this rapidly evolving field. Topics of interest range widely across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

Metrics from SCImago Journal Rank 2025. View on SCImago